Invention Grant
- Patent Title: Marker and diagnosis method for noninvasive diagnosis of myocardial infarction
-
Application No.: US17247534Application Date: 2020-12-15
-
Publication No.: US11718880B2Publication Date: 2023-08-08
- Inventor: Chenggang Yang , Shuguang Li
- Applicant: BEIJING MEDINTELL BIOMED CO., LTD
- Applicant Address: CN Beijing
- Assignee: BEIJING MEDINTELL BIOMED CO., LTD
- Current Assignee: BEIJING MEDINTELL BIOMED CO., LTD
- Current Assignee Address: CN Beijing
- Agency: NKL Law
- Agent Allen Xue
- Priority: CN 1810715884.7 2018.07.03 CN 1810715888.5 2018.07.03 CN 1810717258.1 2018.07.03 CN 1810717286.3 2018.07.03 CN 1810718258.3 2018.07.03 CN 1810718260.0 2018.07.03
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12P19/34 ; C12Q1/6883

Abstract:
The present invention discloses a marker and a diagnosis method for the noninvasive diagnosis of myocardial infarction. According to the method disclosed by the present invention, second-generation sequencing and QPCR methods are used to find that there are significant differences in the expression of ING1, RAE1, DOCK10, KDSR, IVD, and MAEA in the blood of patients with myocardial infarction and normal subjects, that is, the expression of ING1, RAE1, DOCK10, KDSR, IVD and MAEA can be detected to determine whether the subjects suffer from myocardial infarction. According to the correlation between the two, the present invention develops a kit for the diagnosis of the myocardial infarction, and the kit is used for the diagnosis of the myocardial infarction by detecting the expression of ING1, RAE1, DOCK10, KDSR, IVD and MAEA. The diagnostic kit can be used for the early diagnosis of diseases, and has wide application prospect clinically.
Public/Granted literature
- US20210115516A1 Marker and diagnosis method for noninvasive diagnosis of myocardial infarction Public/Granted day:2021-04-22
Information query